Estrogen Variability and Irritability During the Menopause Transition

Last updated: November 18, 2025
Sponsor: University of North Carolina, Chapel Hill
Overall Status: Completed

Phase

4

Condition

Menopause

Oppositional Defiant Disorder (Odd)

Treatment

Placebo

Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release

Progesterone 200 mg

Clinical Study ID

NCT05388656
21-3395
R21MH128241
  • Ages 45-59
  • Female
  • Accepts Healthy Volunteers

Study Summary

Women in the menopause transition (perimenopause) experience substantial day-to-day variability in estradiol and have a 2-4-fold increase in major depression risk. About 40% of perimenopausal women are susceptible to the emergence of affective symptoms tied to changes in estradiol. Among the perimenopausal women with affective impairment, most report irritability, not "depression," is their primary source of impairment and distress. The purpose of this research is to determine the neurophysiologic basis of susceptibility to estradiol fluctuations and irritability symptoms in perimenopausal women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy women 45 - 59 years of age

  • In the early menopause transition (defined by variable menstrual cycle length thatis 7+ days longer or shorter than usual)

  • Increase in irritability since the onset of menstrual cycle changes

  • Moderate to severe irritability symptoms, as defined by IDAS ill-temper scale score >10

  • Have experienced 1+ very stressful life event (e.g. divorce, death of family member)within the past 6 months

  • Negative mammogram within the past two years

  • BMI between 18 - 45 kg/m^2

Exclusion

Exclusion Criteria:

  • Use of psychotropic agents or hormonal preparations, or herbal supplements (otherthan multivitamins) believed to affect mood or menopausal symptoms

  • History of psychosis, bipolar disorder, or substance dependence

  • Active psychological symptoms severe enough to require treatment

  • Current suicidal intent or recent history of suicide attempts (within past 10 years)

  • Personal or family history of cancer indicative of more than average risk forbreast, ovarian or endometrial cancers

  • Personal history of any cardiovascular disease including coronary artery disease,arteriosclerosis, heart attack, stroke

  • Personal history of thromboembolic disorders

  • History of E2-dependent neoplasia

  • History of gallbladder disease

  • Recent history of migraine with aura

  • Blood pressure classified as higher than stage 2 hypertension (≥160 mmHg systolic or ≥100 mmHg diastolic)

  • Liver dysfunction or disease

  • Undiagnosed abnormal genital bleeding

  • Type I diabetes

  • Known sensitivities to the matrix patch system in Climara® or allergy to peanut oilused in Prometrium®

Study Design

Total Participants: 40
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 4
Study Start date:
June 15, 2022
Estimated Completion Date:
January 17, 2025

Study Description

Using a within-subjects, cross-over design and transdermal estradiol to stabilize estradiol fluctuations (and increase levels) the investigators will test if neural dynamics (oscillatory activity in the theta and beta frequencies assessed via EEG) associated with key constructs of irritability (attentional bias to threat and frustration to non-reward) represent a biomarker target of irritability symptom response to transdermal estradiol.

Connect with a study center

  • Carolina Crossing B, Suite 1

    Chapel Hill, North Carolina 27517
    United States

    Site Not Available

  • Carolina Crossing B, Suite 1

    Chapel Hill 4460162, North Carolina 4482348 27517
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.